8 March 2016
CPMP/QWP/159/01
EMEA/CVMP/271/01 Rev. 1*
Committee for Medicinal Products for Veterinary Use (CVMP)

Note for guidance on limitations to the use of ethylene oxide in the manufacture of medicinal products

<table>
<thead>
<tr>
<th>Agreed by Quality Working Party</th>
<th>January 2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adopted by CPMP</td>
<td>March 2001</td>
</tr>
<tr>
<td>Adopted by CVMP</td>
<td>March 2001</td>
</tr>
<tr>
<td>Date for coming into effect</td>
<td>April 2001</td>
</tr>
</tbody>
</table>

* This Rev. 1 revision revises the coverpage (only) of the Note for guidance on limitations to the use of ethylene oxide in the manufacture of medicinal products (CPMP/QWP/159/01 & EMEA/CVMP/271/01 Rev. 1). None of the text of the note for guidance (guideline) has been changed, only the coverpage and the format.

As of 1 January 2016 this Note for Guidance is applicable only to veterinary medicinal products.

The reasons for this restricted applicability are explained in the Concept Paper on a proposal to limit the applicability of the CPMP/CVMP Note for Guidance on Limitations to the Use of Ethylene Oxide in the Manufacture of Medicinal Products (CPMP/QWP/159/01) to veterinary medicinal products (EMA(CHMP/SWP/211900/2015). For medicinal products for human use please refer to ICH guideline M7 on the assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk (EMA/CHMP/ICH/83812/2013).
This note for guidance deals with the use of ethylene oxide in pharmaceutical raw materials, finished products and containers.

1. **Toxicological background**

Ethylene oxide is a substance which, due to its structure, is counted among the very reactive compounds. This reactivity also includes organic structures within cells and cell nuclei. In this case, alkylation and reactions with DNA, RNA and proteins occur. Cytotoxicity, carcinogenicity and mutagenicity of ethylene oxide, which have been demonstrated by many in vitro and in vivo tests, are attributed to these properties.

Epidemiological data from many sources indicates that workers exposed to ethylene oxide at their workplace had an increased incidence of leukaemia and other tumours.

In view of the known positive potential of ethylene oxide for genotoxic carcinogenicity, it is recommended that use is acceptable only when pharmaceutically absolutely necessary, and then residual ethylene oxide in the product should not exceed a limit of 1 ppm. This limit is based on the current limit of detection for ethylene oxide residues.

Any deviation upwards from this limit must be justified with supporting data and defended, taking into account the clinical risk/benefit assessment for the particular products under consideration.

2. **Categories of use of ethylene oxide**

Ethylene oxide is used in the synthesis of pharmaceutical raw materials and as a sterilant. Since it is effective only as a surface sterilant it should be used only when justified and validated on an individual basis.

Ethylene oxide sterilisation should be used only where safer alternatives cannot be used. For containers filled with aqueous products, e.g. pre-filled syringes, the need for a justification for the use of ethylene oxide in the sterilisation of the container prior to filling can be waived provided the container itself fulfills the specification listed under 3.3 as the degradation kinetics of ethylene oxide in an aqueous medium have been sufficiently demonstrated.

3. **Specifications/test procedures**

Due to the above mentioned considerations, the limits are fixed on a mass/mass basis and not on a daily intake basis. If no official test procedure (e.g. Pharmacopoeia) is available a validated test procedure must be proposed by the applicant (see also note for guidance on *Validation of Analytical Procedures: Methodology*).

3.1. **Raw materials**

Specification:

Ethylene oxide: 1 µg/g
Ethylene chlorhydrin (or any other halogenated ethylenehydrine): 50 µg/g.

3.2. **Finished product**

If the residual ethylene oxide originates from its use in the raw starting material, its content must be limited in the raw starting material.
Specification (when used on the finished product):

Ethylene oxide: 1 µg/g

Ethylene chlorhydrin (or any other halogenated ethylenehydrine): 50 µg/g.

### 3.3. Containers

Specification (based on simulated use):

Ethylene oxide: 1 µg/ml (container volume)

Ethylene chlorhydrin (or any other halogenated ethylenehydrine): 50 µg/ml (container volume).